{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:08:09Z","timestamp":1794049689320,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-026-04174-4","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T17:06:23Z","timestamp":1781370383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterizing non-hallucinogenic psychedelics beyond the head twitch response: phenotypic fingerprinting of lisuride and LSD"],"prefix":"10.1038","volume":"16","author":[{"given":"Jillian L.","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin P.","family":"Effinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Basquez-Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janae R.","family":"Wallingford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joselynn R.","family":"Calderon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caden K.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9844-9049","authenticated-orcid":false,"given":"Scott M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"4174_CR1","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619\u201327.","journal-title":"Lancet Psychiatry"},{"key":"4174_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78:481\u20139.","journal-title":"JAMA Psychiatry"},{"key":"4174_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809","volume":"56","author":"R von Rotz","year":"2022","unstructured":"von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinical Med. 2022;56:101809.","journal-title":"EClinical Med."},{"key":"4174_CR4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330:843\u201353.","journal-title":"JAMA"},{"key":"4174_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1176\/appi.ajp.20230887","volume":"182","author":"BA Pagni","year":"2025","unstructured":"Pagni BA, Zeifman RJ, Mennenga SE, Carrithers BM, Goldway N, Bhatt S, et al. Multidimensional personality changes following psilocybin-assisted therapy in patients with alcohol use disorder: results from a double-blind, placebo-controlled clinical trial. Am J Psychiatry. 2025;182:114\u201325.","journal-title":"Am J Psychiatry"},{"key":"4174_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28:983\u201392.","journal-title":"J Psychopharmacol"},{"key":"4174_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40261-022-01122-0","volume":"42","author":"ALV Avancena","year":"2022","unstructured":"Avancena ALV, Kahn JG, Marseille E. The costs and health benefits of expanded access to MDMA-assisted therapy for chronic and severe PTSD in the USA: a modeling study. Clin Drug Investig. 2022;42:243\u201352.","journal-title":"Clin Drug Investig"},{"key":"4174_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1025726","volume":"13","author":"E Marseille","year":"2022","unstructured":"Marseille E, Bertozzi S, Kahn JG. The economics of psychedelic-assisted therapies: a research agenda. Front Psychiatry. 2022;13:1025726.","journal-title":"Front Psychiatry"},{"key":"4174_CR9","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9:3897\u2013902.","journal-title":"Neuroreport"},{"key":"4174_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1021\/acs.chemrev.3c00375","volume":"124","author":"W Duan","year":"2024","unstructured":"Duan W, Cao D, Wang S, Cheng J. Serotonin 2A receptor (5-HT(2A)R) agonists: psychedelics and non-hallucinogenic analogues as emerging antidepressants. Chem Rev. 2024;124:124\u201363.","journal-title":"Chem Rev"},{"key":"4174_CR11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2416106122","volume":"122","author":"JR Tuck","year":"2025","unstructured":"Tuck JR, Dunlap LE, Khatib YA, Hatzipantelis CJ, Weiser Novak S, Rahn RM, et al. Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential. Proc Natl Acad Sci USA. 2025;122:e2416106122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4174_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107933","volume":"167","author":"AL Halberstadt","year":"2020","unstructured":"Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacol. 2020;167:107933.","journal-title":"Neuropharmacol"},{"key":"4174_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00213-013-3006-z","volume":"227","author":"AL Halberstadt","year":"2013","unstructured":"Halberstadt AL, Geyer MA. Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement. Psychopharmacol. (Berl). 2013;227:727\u201339.","journal-title":"Psychopharmacol. (Berl)"},{"key":"4174_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF00401509","volume":"11","author":"SJ Corne","year":"1967","unstructured":"Corne SJ, Pickering RW. A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia. 1967;11:65\u201378.","journal-title":"Psychopharmacologia"},{"key":"4174_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0091-3057(97)00548-0","volume":"60","author":"NA Darmani","year":"1998","unstructured":"Darmani NA. Cocaine and selective monoamine uptake blockers (sertraline, nisoxetine, and GBR 12935) prevent the d-fenfluramine-induced head-twitch response in mice. Pharmacol Biochem Behav. 1998;60:83\u201390.","journal-title":"Pharmacol Biochem Behav"},{"key":"4174_CR16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3389\/fphar.2018.00374","volume":"9","author":"J Gonz\u00e1lez","year":"2018","unstructured":"Gonz\u00e1lez J, Prieto JP, Rodr\u00edguez P, Cavelli M, Benedetto L, Mondino A, et al. Ibogaine acute administration in rats promotes wakefulness, long-lasting REM sleep suppression, and a distinctive motor profile. Front Pharmacol. 2018;9:374.","journal-title":"Front Pharmacol"},{"key":"4174_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0091-3057(96)00161-X","volume":"56","author":"MD Schechter","year":"1997","unstructured":"Schechter MD. Drug-drug discrimination: stimulus properties of drugs of abuse upon a serotonergic-dopaminergic continuum. Pharmacol Biochem Behav. 1997;56:89\u201396.","journal-title":"Pharmacol Biochem Behav"},{"key":"4174_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/BF02246075","volume":"121","author":"D Fiorella","year":"1995","unstructured":"Fiorella D, Rabin RA, Winter JC. Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. II: Reassessment of LSD false positives. Psychopharmacology (Berl). 1995;121:357\u201363.","journal-title":"Psychopharmacology (Berl)"},{"key":"4174_CR19","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/0091-3057(85)90096-6","volume":"23","author":"RA Glennon","year":"1985","unstructured":"Glennon RA, Hauck AE. Mechanistic studies on DOM as a discriminative stimulus. Pharmacol Biochem Behav. 1985;23:937\u201341.","journal-title":"Pharmacol Biochem Behav"},{"key":"4174_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44016-1","volume":"14","author":"J Wallach","year":"2023","unstructured":"Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, et al. Identification of 5-HT(2A) receptor signaling pathways associated with psychedelic potential. Nat Commun. 2023;14:8221.","journal-title":"Nat Commun"},{"key":"4174_CR21","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1021\/acsptsci.3c00192","volume":"7","author":"GC Glatfelter","year":"2024","unstructured":"Glatfelter GC, Pottie E, Partilla JS, Stove CP, Baumann MH. Comparative pharmacological effects of lisuride and lysergic acid diethylamide revisited. ACS Pharmacol Transl Sci. 2024;7:641\u201353.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"4174_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00213-002-1141-z","volume":"164","author":"D Marona-Lewicka","year":"2002","unstructured":"Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE. Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacol (Berl). 2002;164:93\u2013107.","journal-title":"Psychopharmacol (Berl)"},{"key":"4174_CR23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1177\/02698811251330741","volume":"39","author":"J Kehler","year":"2025","unstructured":"Kehler J, Lindskov MST. Are the LSD-analogs lisuride and ergotamine examples of non-hallucinogenic serotonin 5-HT2A receptor agonists?. J Psychopharmacol. 2025;39:889\u201395.","journal-title":"J Psychopharmacol"},{"key":"4174_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonzalez-Maeso","year":"2007","unstructured":"Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53:439\u201352.","journal-title":"Neuron"},{"key":"4174_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1233743","volume":"10","author":"VM Pogorelov","year":"2023","unstructured":"Pogorelov VM, Rodriguiz RM, Roth BL, Wetsel WC. The G protein biased serotonin 5-HT2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice. Front Mol Biosci. 2023;10:1233743.","journal-title":"Front Mol Biosci"},{"key":"4174_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118348","volume":"190","author":"A Bouloufa","year":"2025","unstructured":"Bouloufa A, Delcourte S, Rovera R, Delannay T, Duquet A, Mouledous L, et al. LSD\u2019s rapid antidepressant effects are modulated by 5-HT2B receptors. Biomed Pharmacother. 2025;190:118348.","journal-title":"Biomed Pharmacother"},{"key":"4174_CR27","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","volume":"11","author":"M Hibicke","year":"2020","unstructured":"Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD. Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Chem Neurosci. 2020;11:864\u201371.","journal-title":"ACS Chem Neurosci"},{"key":"4174_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/BF03189490","volume":"6","author":"M Humpel","year":"1981","unstructured":"Humpel M, Toda T, Oshino N, Pommerenke G. The pharmacokinetics of lisuride hydrogen maleate in rat, rabbit and rhesus monkey. Eur J Drug Metab Pharmacokinet. 1981;6:207\u201319.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"4174_CR29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/BF02158503","volume":"11","author":"A Stoll","year":"1955","unstructured":"Stoll A, Rothlin E, Rutschmann J, Schalch WR. Distribution and fate of 14C-labeled lysergic acid diethylamide (LSD 25) in the animal body. Experientia. 1955;11:396\u20137.","journal-title":"Experientia"},{"key":"4174_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2022.100473","volume":"20","author":"AB Cole","year":"2022","unstructured":"Cole AB, Montgomery K, Bale TL, Thompson SM. What the hippocampus tells the HPA axis: Hippocampal output attenuates acute stress responses via disynaptic inhibition of CRF+ PVN neurons. Neurobiol Stress. 2022;20:100473.","journal-title":"Neurobiol Stress"},{"key":"4174_CR31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41386-023-01739-5","volume":"49","author":"KR Montgomery","year":"2024","unstructured":"Montgomery KR, Bridi MS, Folts LM, Marx-Rattner R, Zierden HC, Wulff AB, et al. Chemogenetic activation of CRF neurons as a model of chronic stress produces sex-specific physiological and behavioral effects. Neuropsychopharmacol. 2024;49:443\u201354.","journal-title":"Neuropsychopharmacol"},{"key":"4174_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.expneurol.2010.09.008","volume":"227","author":"NM Ben Abdallah","year":"2011","unstructured":"Ben Abdallah NM, Fuss J, Trusel M, Galsworthy MJ, Bobsin K, Colacicco G, et al. The puzzle box as a simple and efficient behavioral test for exploring impairments of general cognition and executive functions in mouse models of schizophrenia. Exp Neurol. 2011;227:42\u201352.","journal-title":"Exp Neurol"},{"key":"4174_CR33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.biopsych.2021.11.024","volume":"92","author":"TA Troppoli","year":"2022","unstructured":"Troppoli TA, Zanos P, Georgiou P, Gould TD, Rudolph U, Thompson SM. Negative allosteric modulation of gamma-aminobutyric acid A receptors at alpha5 subunit-containing benzodiazepine sites reverses stress-induced anhedonia and weakened synaptic function in mice. Biol Psychiatry. 2022;92:216\u201326.","journal-title":"Biol Psychiatry"},{"key":"4174_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jneumeth.2003.10.009","volume":"134","author":"A Delorme","year":"2004","unstructured":"Delorme A, Makeig S. EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Methods. 2004;134:9\u201321.","journal-title":"J Neurosci Methods"},{"key":"4174_CR35","doi-asserted-by":"publisher","first-page":"12374","DOI":"10.1111\/jne.12374","volume":"28","author":"P Strajhar","year":"2016","unstructured":"Strajhar P, Schmid Y, Liakoni E, Dolder PC, Rentsch KM, Kratschmar DV, et al. Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects. J Neuroendocrinol. 2016;28:12374.","journal-title":"J Neuroendocrinol"},{"key":"4174_CR36","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S0022-3565(25)21892-4","volume":"229","author":"GE Martin","year":"1984","unstructured":"Martin GE, Bendesky RJ. Mouse locomotor activity: an in vivo test for dopamine autoreceptor activation. J Pharmacol Exp Therapeutics. 1984;229:706\u201311.","journal-title":"J Pharmacol Exp Therapeutics"},{"key":"4174_CR37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0893-133X(97)00164-4","volume":"18","author":"K Krebs-Thomson","year":"1998","unstructured":"Krebs-Thomson K, Paulus MP, Geyer MA. Effects of hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A and 5-HT2C receptors. Neuropsychopharmacol. 1998;18:339\u201351.","journal-title":"Neuropsychopharmacol"},{"key":"4174_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96736-3","volume":"11","author":"R Rodriguiz","year":"2021","unstructured":"Rodriguiz R, Nadkarni V, Means CR, Pogorelov VM, Chiu YT, Roth BL, et al. LSD-stimulated behaviors in mice require beta-arrestin 2 but not beta-arrestin 1. Sci Rep. 2021;11:17690.","journal-title":"Sci Rep"},{"key":"4174_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49741-9","volume":"15","author":"DP Effinger","year":"2024","unstructured":"Effinger DP, Hoffman JL, Mott SE, Magee SN, Quadir SG, Rollison CS, et al. Increased reactivity of the paraventricular nucleus of the hypothalamus and decreased threat responding in male rats following psilocin administration. Nat Commun. 2024;15:5321.","journal-title":"Nat Commun"},{"key":"4174_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/psymed.2024.0011","volume":"3","author":"DJ Kruger","year":"2025","unstructured":"Kruger DJ, Aday JS, Fields CW, Kolbman N, Glynos N, Barron J, et al. Psychedelic therapist sexual misconduct and other adverse experiences among a sample of naturalistic psychedelic users. Psychedelic Med (New Rochelle). 2025;3:41\u201347.","journal-title":"Psychedelic Med (New Rochelle)"},{"key":"4174_CR41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.biopsych.2008.03.013","volume":"64","author":"P Celada","year":"2008","unstructured":"Celada P, Puig MV, Diaz-Mataix L, Artigas F. The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: reversal by antipsychotic drugs. Biol Psychiatry. 2008;64:392\u2013400.","journal-title":"Biol Psychiatry"},{"key":"4174_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16325-w","volume":"12","author":"CT Golden","year":"2022","unstructured":"Golden CT, Chadderton P. Psilocybin reduces low frequency oscillatory power and neuronal phase-locking in the anterior cingulate cortex of awake rodents. Sci Rep. 2022;12:12702.","journal-title":"Sci Rep"},{"key":"4174_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.177198","volume":"987","author":"Y Wang","year":"2025","unstructured":"Wang Y, Jiang K, Yao Y, Liu X, Su R. A comparative study of effects of DOM and lisuride on neuronal activity in nucleus accumbens of freely moving rats. Eur J Pharmacol. 2025;987:177198.","journal-title":"Eur J Pharmacol"},{"key":"4174_CR44","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1073\/pnas.1518377113","volume":"113","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci USA. 2016;113:4853\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4174_CR45","doi-asserted-by":"publisher","first-page":"15171","DOI":"10.1523\/JNEUROSCI.2063-13.2013","volume":"33","author":"SD Muthukumaraswamy","year":"2013","unstructured":"Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ, Brookes MJ, Williams TM, Errtizoe D, et al. Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci. 2013;33:15171\u201383.","journal-title":"J Neurosci"},{"key":"4174_CR46","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1177\/0269881121991569","volume":"35","author":"A Inserra","year":"2021","unstructured":"Inserra A, De Gregorio D, Rezai T, Lopez-Canul MG, Comai S, Gobbi G. Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice. J Psychopharmacol. 2021;35:469\u201382.","journal-title":"J Psychopharmacol"},{"key":"4174_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/srep46421","volume":"7","author":"MM Schartner","year":"2017","unstructured":"Schartner MM, Carhart-Harris RL, Barrett AB, Seth AK, Muthukumaraswamy SD. Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Sci Rep. 2017;7:46421.","journal-title":"Sci Rep"},{"key":"4174_CR48","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41386-024-01809-2","volume":"49","author":"CH Murray","year":"2014","unstructured":"Murray CH, Frohlich J, Haggarty CJ, Tare I, Lee R, de Wit H. Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine. Neuropsychopharmacol. 2014;49:1120\u20138.","journal-title":"Neuropsychopharmacol"},{"key":"4174_CR49","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41594-018-0116-7","volume":"25","author":"JD McCorvy","year":"2018","unstructured":"McCorvy JD, Wacker D, Wang S, Agegnehu B, Liu J, Lansu K, et al. Structural determinants of 5-HT(2B) receptor activation and biased agonism. Nat Struct Mol Biol. 2018;25:787\u201396.","journal-title":"Nat Struct Mol Biol"},{"key":"4174_CR50","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/cercor\/bhg128","volume":"14","author":"M Amargos-Bosch","year":"2004","unstructured":"Amargos-Bosch M, Bortolozzi A, Puig MV, Serrats J, Adell A, Celada P, et al. Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex. 2004;14:281\u201399.","journal-title":"Cereb Cortex"},{"key":"4174_CR51","doi-asserted-by":"crossref","unstructured":"Chiu YT, Deutch AY, Wang W, Schmitz GP, Huang KL, Kocak DD A suite of engineered mice for interrogating psychedelic drug actions. bioRxiv. 2023; Sep 26:2023.09.25.559347.","DOI":"10.1101\/2023.09.25.559347"},{"key":"4174_CR52","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00213-009-1718-x","volume":"208","author":"AL Halberstadt","year":"2010","unstructured":"Halberstadt AL, Geyer MA. LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor. Psychopharmacol (Berl). 2010;208:179\u201389.","journal-title":"Psychopharmacol (Berl)"},{"key":"4174_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112203","volume":"42","author":"V Lewis","year":"2023","unstructured":"Lewis V, Bonniwell EM, Lanham JK, Ghaffari A, Sheshbaradaran H, Cao AB, et al. A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Cell Rep. 2023;42:112203.","journal-title":"Cell Rep"},{"key":"4174_CR54","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1021\/acschemneuro.4c00513","volume":"15","author":"GC Glatfelter","year":"2024","unstructured":"Glatfelter GC, Clark AA, Cavalco AN, Landavazo A, Partilla JS, Naeem M, et al. Serotonin 1A receptors modulate serotonin 2A receptor-mediated behavioral effects of 5-Methoxy-N,N-dimethyltryptamine analogs in mice. ACS Chem Neurosci. 2024;15:4458\u201377.","journal-title":"ACS Chem Neurosci"},{"key":"4174_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1140656","volume":"14","author":"K Egger","year":"2023","unstructured":"Egger K, Gudmundsen F, Jessen NS, Baun C, Poetzsch SN, Shalgunov V, et al. A pilot study of cerebral metabolism and serotonin 5-HT(2A) receptor occupancy in rats treated with the psychedelic tryptamine DMT in conjunction with the MAO inhibitor harmine. Front Pharmacol. 2023;14:1140656.","journal-title":"Front Pharmacol"},{"key":"4174_CR56","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1177\/0271678X241302937","volume":"45","author":"FA Bagdasarian","year":"2025","unstructured":"Bagdasarian FA, Larsen K, Deng HP, Fisher PM, Mandeville JB, Sander CY, et al. Neurochemical characterization of 5-HT(2A)R partial agonists with simultaneous PET-MRI. J Cereb Blood Flow Metab. 2025;45:908\u201319.","journal-title":"J Cereb Blood Flow Metab"},{"key":"4174_CR57","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/jnnp.44.4.347","volume":"44","author":"AJ Lees","year":"1981","unstructured":"Lees AJ, Bannister R. The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy-Drager syndrome). J Neurol Neurosurg Psychiatry. 1981;44:347\u201351.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04174-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04174-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04174-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:03:46Z","timestamp":1787231026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04174-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4174"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-04174-4","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SMT is listed as an inventor on patents filed by the University of Maryland Baltimore concerning treatment of psychiatric disease with psychedelics, serves on the Scientific Advisory Board of Terran Biosciences and Definium Therapeutics, and is a co-founder of ProNovo Therapeutics. The other authors report no conflicts.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"421"}}